👉 Momentum doesn’t die from bad science. It dies from regulatory surprises. In early-stage biotech, regulatory risk is the fastest way to lose investor confidence . Yet most founders stay focused on preclinical data, proof of concept, and technical milestones. Investors, on the other hand, are scanning for predictability, compliance, and clarity . And when those signals are missing, even a brilliant scientific program can stall. 👉 Trust erodes quietly, and the runway disapp

Most biotech CEOs fail not on science, but on scale. This expanded framework reveals the three blind spots—pipeline chaos, headcount traps, and investor readiness—that stall growth.